<DOC>
	<DOCNO>NCT01250158</DOCNO>
	<brief_summary>The purpose study determine whether PILP-kit safely use , within specific performance parameter , isolate perfuse liver chemotherapeutic drug treatment patient unresectable liver metastasis .</brief_summary>
	<brief_title>Liver-PILP First-in-Man</brief_title>
	<detailed_description>The objective Medical Device Study , demonstrate feasibility liver PILP intervention . The liver PILP intervention consider feasible procedure demonstrate safe liver PILP kit performs accord specification .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>1 . Subjects ECOG ( Eastern Cooperative Oncology Group ) stag 0 1 2 . Unresectable metastatic disease predominant liver 1 . More 60 % tumor involve liver tissue 2 . Abnormal vascular anatomy 3 . Severe atherosclerosis 4 . Dissection and/or thrombotic occlusion and/or aneurysm aorta , iliac hepatic artery 5 . Short suprahepatic vena cava segment ( &lt; 1.5 cm ) 6 . One jugular vein occlude 7 . Other severe , concomitant disease regard subject status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Liver Percutaneous Isolated Localized Perfusion</keyword>
	<keyword>PILP</keyword>
	<keyword>Isolated Hepatic Perfusion</keyword>
	<keyword>IHP</keyword>
	<keyword>Liver metastasis</keyword>
	<keyword>Unresectable liver metastasis different etiology</keyword>
</DOC>